Peptide Schedule
AICAR (Acadesine)Small moleculeNo amino acid sequence. Icon reflects category theme only.AICAR (Acadesine)
Benefits
About AICAR (Acadesine)
AICAR (5-aminoimidazole-4-carboxamide ribonucleoside), also known as acadesine, is a cell-permeable nucleoside analog that acts as a potent activator of AMP-activated protein kinase (AMPK). Once inside the cell, it's phosphorylated by adenosine kinase into ZMP — a compound that mimics AMP and directly activates AMPK, the body's master metabolic energy sensor. This triggers many of the same metabolic pathways that exercise does, earning AICAR its reputation as an "exercise in a pill." AICAR first gained scientific attention in the early 1990s as a potential cardioprotective agent during bypass surgery. Researchers at PeriCor Therapeutics studied it in over 4,000 cardiac surgery patients to reduce ischemic injury. That research stalled after a phase III futility analysis in 2010, but interest in AICAR exploded in a different direction when a landmark 2008 study showed it could increase running endurance in sedentary mice by 44% without any actual exercise. The compound became infamous in professional cycling after reports surfaced during the 2013 and 2019 Tour de France that riders were allegedly using powdered AICAR as a performance enhancer. WADA added it to the Prohibited List in 2009 under the category of Hormone and Metabolic Modulators, and anti-doping laboratories developed specific detection methods for AICAR and its metabolite ZMP. Beyond exercise mimicry, AICAR shows promise in research on type 2 diabetes, diabetic neuropathy, and obesity-related metabolic dysfunction. A 2025 study demonstrated that AICAR administration could prevent and reverse diabetic polyneuropathy through mitophagy regulation (PMID 39766089). It also has documented AMPK-independent effects on tumor suppressor activation, adenosine signaling, and cellular stress responses.
Who Should Consider AICAR (Acadesine)
- Researchers studying AMPK-mediated metabolic regulation
- Adults with metabolic syndrome or insulin resistance (research context only)
- Individuals investigating exercise mimetic compounds for periods of immobility
- Scientists studying diabetic neuropathy and mitophagy pathways
- Anti-doping researchers developing detection methodologies
How AICAR (Acadesine) Works
AICAR enters cells through adenosine transporters due to its structural similarity to adenosine. Once intracellular, adenosine kinase phosphorylates it into ZMP (AICA ribotide, also called AICAR monophosphate). ZMP mimics AMP and binds to the gamma subunit of AMP-activated protein kinase (AMPK), triggering allosteric activation of the kinase complex. This is the same energy-sensing pathway that fires during exercise when ATP levels drop and AMP accumulates. Activated AMPK then phosphorylates downstream targets across multiple metabolic pathways. It stimulates GLUT4 translocation to the cell membrane, increasing glucose uptake in skeletal muscle independent of insulin. It activates acetyl-CoA carboxylase (ACC) phosphorylation, which reduces malonyl-CoA and unlocks mitochondrial fatty acid beta-oxidation. AMPK also turns on PGC-1alpha signaling, which drives mitochondrial biogenesis and slow-twitch (type I) muscle fiber specification — the same fiber type remodeling that occurs with endurance training. Importantly, AICAR also has well-documented AMPK-independent effects. ZMP inhibits fructose-1,6-bisphosphatase and other enzymes in the purine biosynthesis pathway. It competes with adenosine for nucleoside transporters, raising extracellular adenosine concentrations and activating adenosine receptor signaling. A 2018 study showed AICAR activates the tumor suppressors LATS1 and LATS2 through an AMPK-independent mechanism (PMID 29730476).
What to Expect
AMPK activation begins at the cellular level. No outward changes are expected yet. Some users report a subtle increase in energy or warmth. Monitor injection sites for reactions.
Fatty acid oxidation rates start to increase. Mild improvements in exercise tolerance may become noticeable. Blood glucose may trend slightly lower in insulin-resistant subjects. Uric acid levels should be monitored.
Peak metabolic effects within a 14-day cycle. Endurance and fat metabolism improvements are most pronounced. Animal data showed 44% endurance gains at comparable timepoints. Body composition shifts may become measurable.
Final days of the recommended cycle window. Cumulative AMPK activation should be at its highest. Discontinue at day 14 to prevent accumulation-related side effects. Benefits persist for several days after the last dose.
Metabolic benefits gradually return to baseline over 1-2 weeks. AMPK activity normalizes as ZMP clears. Maintain exercise and dietary habits gained during the cycle. Wait at least 4-8 weeks before considering another cycle.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 25mg | Daily |
| Aggressive | 50mg | EOD |
Note: AMPK activator and exercise mimetic. Banned by WADA since 2009. Max 14-day cycles with 1-2 month washout. Start low due to potential renal stress at high doses. Not approved for human therapeutic use.
How to Inject AICAR (Acadesine)
Inject subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites systematically to prevent lipohypertrophy. Inject slowly and steadily. AICAR is best administered in the morning to align with natural metabolic rhythms. Stay well-hydrated during use to support renal clearance. Consider prophylactic allopurinol if prone to hyperuricemia.
Cycling Protocol
AICAR should not be used for longer than 14 consecutive days due to accumulation toxicity and renal stress risk. Allow at least 4-8 weeks of washout between cycles. No more than 3 cycles per year. Monitor kidney function and uric acid levels during use.
Pharmacokinetics
Source: Estimated from clinical pharmacokinetic data in cardiac surgery patients. AICAR has a short plasma half-life due to rapid cellular uptake and phosphorylation to ZMP. Intracellular ZMP persists longer (PMID 7818622).
Loading the interactive decay curve.
Side Effects
Hyperuricemia (elevated uric acid) is the most common effect at higher doses — typically managed with allopurinol. Transient injection site reactions including redness and swelling. At elevated doses (>200 mg/kg IV in clinical trials): transient anemia, thrombocytopenia, renal impairment, and hypotension have been reported. GI effects like nausea, bloating, and abdominal discomfort are possible. Chronic AMPK overactivation may theoretically promote muscle atrophy through FoxO3-mediated autophagy.
Contraindications
- Pregnancy or breastfeeding — no reproductive safety data exists
- Chronic kidney disease or impaired renal function — AICAR and ZMP are renally cleared and may worsen kidney stress
- Active gout or hyperuricemia — AICAR elevates uric acid levels
- Hypoglycemia or insulin-dependent diabetes without medical supervision — AMPK activation lowers blood glucose
- Children and adolescents under 18 — not studied in pediatric populations
- Active malignancy — AMPK activation has context-dependent effects on tumor growth
- Competitive athletes subject to WADA testing — AICAR has been on the Prohibited List since 2009
Drug Interactions
- Metformin and other AMPK activators — additive AMPK stimulation may cause excessive glucose lowering or lactic acidosis risk; avoid stacking
- Insulin and sulfonylureas — combined insulin-sensitizing effects increase hypoglycemia risk significantly
- Allopurinol — commonly co-administered to manage AICAR-induced hyperuricemia; monitor uric acid levels
- Adenosine receptor agonists (dipyridamole, regadenoson) — AICAR raises extracellular adenosine, potentially amplifying cardiovascular effects
- Anticoagulants — transient thrombocytopenia has been observed at high AICAR doses; monitor platelet counts
- Nucleoside analog drugs (ribavirin, acyclovir) — potential competition for nucleoside transporters may alter drug uptake
Storage & Stability
Related Peptides
References
- AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review (Cells 2021)PubMed 34064363
- AMPK and PPARdelta agonists are exercise mimetics (Narkar et al., Cell 2008)PubMed 18674809
- AICAR Antiproliferative Properties Involve the AMPK-Independent Activation of the Tumor Suppressors LATS 1 and 2 (Mol Ther 2018)PubMed 29730476
- Administration of AICAR Prevents and Reverses Diabetic Polyneuropathy by Regulating Mitophagy (Int J Mol Sci 2025)PubMed 39766089
- An initial multicenter randomized controlled trial on the safety and efficacy of acadesine in patients undergoing CABG surgery (J Am Coll Cardiol 1995)PubMed 7818622
- Metabolic modulators of the exercise response: doping control analysis of GW501516 and AICAR (Drug Test Anal 2015)PubMed 25179079